title: Trends in systemic psoriasis treatment therapies from 1993 through 2010.
abstract: BACKGROUND
  Moderate-to-severe psoriasis generally requires systemic therapy, and is often undertreated.
  
  
  OBJECTIVE
  To determine and analyze what courses of treatment and in what frequency are being utilized to combat psoriasis in the United States.
  
  
  METHODS
  Analysis of data from the National Ambulatory Medical Care Survey (NAMCS) and National Hospital Ambulatory Medical Care Survey (NHAMCS) of the National Center for Health Statistics. Data were analyzed to examine the prevalence of different therapy techniques to combat psoriasis from 1993 through 2010. The trends for phototherapy, methotrexate (MTX), retinoids, cyclosporine A (CSA), systemic steroids, and biologics were all analyzed over the entire 18-year period and independently before and after the introduction of biologics in 2002.
  
  
  RESULTS
  From 1993 to 2010, the trend for total systemic treatments has not significantly increased (P=0.5). Frequency of phototherapy treatments significantly decreased from 1993 to 2010 (P<0.001). Since the introduction of biologics in 2002, their frequency has significantly increased, becoming the most frequently used treatment from 2008-2010 (P<0.0001).
  
  
  CONCLUSIONS
  Severity of psoriasis was not recorded in the NAMCS and NHAMCS.
  
  
  CONCLUSIONS
  The frequency of systemic treatments to treat psoriasis has not significantly increased from 1993 to 2010. Despite the introduction of biologics, it appears that little progress has been made in reducing under-treatment of moderate-to-severe psoriasis.
authors.forename: Meredith K
authors.initials: MK
authors.lastname: Shaw
authors.forename: Scott A
authors.initials: SA
authors.lastname: Davis
authors.forename: Steven R
authors.initials: SR
authors.lastname: Feldman
authors.forename: Alan B
authors.initials: AB
authors.lastname: Fleischer
mesh_terms: D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D016572:Cyclosporine / Q000008:administration & dosage; D003879:Dermatologic Agents / Q000008:administration & dosage*; D003880:Dermatology / Q000639:trends*; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage; D010789:Phototherapy / Q000706:statistics & numerical data; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology; D012176:Retinoids / Q000008:administration & dosage; D012720:Severity of Illness Index; D011795:Surveys and Questionnaires; D014481:United States
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D012176:Retinoids; D016572:Cyclosporine; D008727:Methotrexate